Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy
AbstractImmunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a frequent cause of kidney failure. Currently, the diagnosis necessitates a kidney biopsy, with routine immunofluorescence microscopy revealing IgA as the dominant or co-dominant immunoglobulin in the glomerular immuno- deposits, often with IgG and sometimes IgM or both. Complement protein C3 is observed in most cases. IgAN leads to kidney failure in 20–40% of patients within 20 years of diagnosis and reduces average life expectancy by about 10 years. There is increasing clinical, biochemical, and genetic eviden ce ...
Source: Drugs - September 25, 2023 Category: Drugs & Pharmacology Source Type: research
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments
AbstractAlcohol is a prominent cause of liver disease worldwide with higher prevalence in developed nations. The spectrum of alcohol-associated liver disease (ALD) encompasses a diverse range of clinical entities, from asymptomatic isolated steatosis to decompensated cirrhosis, and in some cases, acute or chronic liver failure. Consequently, it is important for healthcare practitioners to maintain awareness and systematically screen for ALD. The optimal evaluation and management of ALD necessitates a collaborative approach, incorporating a multidisciplinary team and accounting for concurrent medical conditions. A repertoir...
Source: Drugs - September 25, 2023 Category: Drugs & Pharmacology Source Type: research
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
AbstractOvarian cancer is the leading cause of gynecological cancer death. Improved understanding of the biologic pathways and introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) during the last decade have changed the treatment landscape. This has improved outcomes, but unfortunately half the women with ovarian cancer still succumb to the disease within 5 years of diagnosis. Pathways of resistance to PARPi and chemotherapy have been studied extensively, but there is an unmet need to overcome treatment failure and improve outcome. Major mechanisms of PARPi resistance include restoration of homologous recombin...
Source: Drugs - September 22, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa
(Source: Drugs)
Source: Drugs - September 21, 2023 Category: Drugs & Pharmacology Source Type: research
Alzheimer ’s Disease: Novel Targets and Investigational Drugs for Disease Modification
AbstractNovel agents addressing non-amyloid, non-tau targets in Alzheimer ’s Disease (AD) comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most of the target processes identified in the Common Alzheimer’s Disease Research Ontology (CADRO) are represented by novel agents in trials. Inflammation and synaptic plasticity/neuroprotec tion are the CADRO categories with the largest number of novel candidate therapies. Within these categories, there are few overlapping targets among the test agents. Additional categories being evaluated include apolipoprotein E\(\varepsilon\) 4 (APOE4) e...
Source: Drugs - September 20, 2023 Category: Drugs & Pharmacology Source Type: research
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
In conclusion, vutrisiran is an efficacious and generally well-tolerated alternative option for the treatment of polyneuropathy of hATTR amyloidosis, which has the potential advantage of infrequent subcutaneous dosage. (Source: Drugs)
Source: Drugs - September 20, 2023 Category: Drugs & Pharmacology Source Type: research
Alzheimer ’s Disease: Novel Targets and Investigational Drugs for Disease Modification
AbstractNovel agents addressing non-amyloid, non-tau targets in Alzheimer ’s Disease (AD) comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most of the target processes identified in the Common Alzheimer’s Disease Research Ontology (CADRO) are represented by novel agents in trials. Inflammation and synaptic plasticity/neuroprotec tion are the CADRO categories with the largest number of novel candidate therapies. Within these categories, there are few overlapping targets among the test agents. Additional categories being evaluated include apolipoprotein E\(\varepsilon\) 4 (APOE4) e...
Source: Drugs - September 20, 2023 Category: Drugs & Pharmacology Source Type: research
Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
AbstractAfter more than 2 decades of recommending an escalating strategy for the treatment of most patients with multiple sclerosis, there has recently been considerable interest in the use of high-efficacy therapies in the early stage of the disease. Early intervention with induction/high-efficacy disease-modifying therap y may have the best risk-benefit profile for patients with relapsing-remitting multiple sclerosis who are young and have active disease, numerous focal T2 lesions on spinal and brain magnetic resonance imaging, and no irreversible disability. Although we have no curative treatment, at least seven cl as...
Source: Drugs - September 19, 2023 Category: Drugs & Pharmacology Source Type: research
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
ConclusionsThere exists first-class evidence that documents the efficacy and tolerability of stiripentol, pharmaceutical-grade cannabidiol, fenfluramine hydrochloride, and soticlestat for the treatment of seizures associated with DS, and allows discussion about the expected outcomes regarding seizure frequency reduction and tolerability profiles. (Source: Drugs)
Source: Drugs - September 11, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Remdesivir: A Review in COVID-19
(Source: Drugs)
Source: Drugs - September 4, 2023 Category: Drugs & Pharmacology Source Type: research
